ArticleThe oncologist2016
Early Recurrence After Hepatectomy for Colorectal Liver Metastases: What Optimal Definition and What Predictive Factors?
Article in The oncologist, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07391007 (A Multidimensional Early-Recurrence Risk Stratification System and Personalized Treatment for Colorectal Cancer Liver Metastases), which is not on this map. Cited by 73 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Multidimensional Early-Recurrence Risk Stratification System and Personalized Treatment for Colorectal Cancer Liver Metastases: A Prospective Clinical Study
Who cites it
73 citing papers in PubMed, 2 syntheses or guidelines pooled it, 153 citations in OpenAlex.
- Prognostic factors associated with early recurrence following liver resection for colorectal liver metastases: a systematic review and meta-analysis.BMC cancer · 2024Pooled it
- Parenchymal-Sparing Versus Anatomic Liver Resection for Colorectal Liver Metastases: a Systematic Review.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2017Pooled it
- Trial
- First-Line Systemic Treatment for Initially Unresectable Colorectal Liver Metastases: Post Hoc Analysis of the CAIRO5 Randomized Clinical Trial.JAMA oncology · 2025Trial
- Trial
- A Model to Predict Treatment Failure in Patients Undergoing Upfront Surgery for Resectable Colorectal Liver Metastases.Annals of surgical oncology · 2023Trial
- Recurrence patterns stratify post-progression survival after early recurrence of colorectal liver metastases following hepatectomy: a single-center retrospective study.World journal of surgical oncology · 2026Article
- Prognostic Role of CA19-9 in Patients Undergoing Hepatectomy for Colorectal Liver Metastases.Cancers · 2026Review
- One-Year Mortality after Hepatectomy: Defining a Novel Quality Metric.Annals of surgical oncology · 2026Article
- Prognostic Value of Circulating Tumor DNA for Recurrence and Survival in Patients Undergoing Local Treatment for Initially Unresectable RAS/RAF Mutated Colorectal Cancer Liver Metastases.Annals of surgical oncology · 2026Article
- Feedback regulation between histone H3 lysine 18 lactylation and TROP2-mediated glycolysis drives metastatic progression of colorectal cancer.Clinical and translational medicine · 2026Article
- A clinical-molecular nomogram for predicting early recurrence following resection of initially unresectable colorectal liver metastases.Therapeutic advances in medical oncology · 2026Article
- Integration of near-infrared fluorescence imaging and Sonazoid contrast-enhanced ultrasound in laparoscopic resection of colorectal liver metastases: a dual-center retrospective study.Surgical endoscopy · 2025Article
- Article
- A CT-based radiomics tumor quality and quantity model to predict early recurrence after radical surgery for colorectal liver metastases.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Article
- Gamma-Glutamyl Transferase Plus Carcinoembryonic Antigen Ratio Index: A Promising Biomarker Associated with Treatment Response to Neoadjuvant Chemotherapy for Patients with Colorectal Cancer Liver Metastases.Current oncology (Toronto, Ont.) · 2025Article
- Predicting one-year post-surgical recurrence in colorectal liver metastasis using CT radiomics and machine learning.PloS one · 2025Article
- Predicting early recurrence of colorectal cancer liver metastases: an integrative approach using radiomics and machine learning.Frontiers in oncology · 2025Article
- Neoadjuvant chemotherapy combined with bevacizumab for resectable colorectal liver metastasis with risk factors for recurrence: a multicenter real-world study.Therapeutic advances in medical oncology · 2025Article
- Chromosomal instability is associated with prognosis and efficacy of bevacizumab after resection of colorectal cancer liver metastasis.Annals of medicine · 2024Article
13 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe purpose of this study was to determine the optimal definition and elucidate the predictive factors of early recurrence after surgery for colorectal liver metastases (CRLM).
methodsAmong 987 patients who underwent curative surgery for CRLM from 1990 to 2012, 846 with a minimum follow-up period of 24 months were eligible for this study. The minimum p value approach of survival after initial recurrence was used to determine the optimal cutoff for the definition of early recurrence. The predictive factors of early recurrence and prognostic factors of survival were analyzed.
resultsFor 667 patients (79%) who developed recurrence, the optimal cutoff point of early recurrence was determined to be 8 months after surgery. The impact of early recurrence on survival was demonstrated mainly in patients who received preoperative chemotherapy. Among the 691 patients who received preoperative chemotherapy, recurrence was observed in 562 (81%), and survival in patients with early recurrence was significantly worse than in those with late recurrence (5-year survival 18.5% vs. 53.4%, p < .0001). Multivariate logistic analysis identified age ≤57 years (p = .0022), >1 chemotherapy line (p = .03), disease progression during last-line chemotherapy (p = .024), >3 tumors (p = .0014), and carbohydrate antigen 19-9 >60 U/mL (p = .0003) as independent predictors of early recurrence. Salvage surgery for recurrence significantly improved survival, even in patients with early recurrence.
conclusionThe optimal cutoff point of early recurrence was determined to be 8 months. The preoperative prediction of early recurrence is possible and crucial for designing effective perioperative chemotherapy regimens. IMPLICATIONS FOR PRACTICE: In this study, the optimal cutoff point of early recurrence was determined to be 8 months after surgery based on the minimum p value approach, and its prognostic impact was demonstrated mainly in patients who received preoperative chemotherapy. Five factors, including age, number of preoperative chemotherapy lines, response to last-line chemotherapy, number of tumors, and carbohydrate antigen 19-9 concentrations, were identified as predictors of early recurrence. Salvage surgery for recurrence significantly improved survival, even in patients with early recurrence. For better selection of patients who could truly benefit from surgery and should also receive strong postoperative chemotherapy, the accurate preoperative prediction of early recurrence is crucial.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.